Compare BHK & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BHK | AQST |
|---|---|---|
| Founded | 2001 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 687.6M | 707.6M |
| IPO Year | N/A | 2018 |
| Metric | BHK | AQST |
|---|---|---|
| Price | $9.65 | $3.28 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $8.83 |
| AVG Volume (30 Days) | 188.3K | ★ 5.9M |
| Earning Date | 01-01-0001 | 03-04-2026 |
| Dividend Yield | ★ 8.34% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.03 | N/A |
| Revenue | N/A | ★ $43,397,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $43.02 |
| P/E Ratio | $10.42 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.02 | $2.12 |
| 52 Week High | $11.09 | $7.55 |
| Indicator | BHK | AQST |
|---|---|---|
| Relative Strength Index (RSI) | 56.00 | 20.39 |
| Support Level | $9.60 | $3.21 |
| Resistance Level | $9.69 | $3.60 |
| Average True Range (ATR) | 0.05 | 0.34 |
| MACD | 0.01 | -0.31 |
| Stochastic Oscillator | 71.88 | 2.81 |
Blackrock Core Bond Trust is a closed-ended management investment company. Its objective is to provide current income and capital appreciation. The trust seeks to achieve its investment objective by investing a majority of its managed assets in bonds that are investment-grade quality at the time of investment. The trust's investments will include a broad range of bonds, including corporate bonds, U.S. government and agency securities and mortgage-related securities.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.